<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001805" GROUP_ID="PREG" ID="539199072309501548" MERGED_FROM="" MODIFIED="2009-11-11 14:00:52 +0100" MODIFIED_BY="Sonja Henderson" NOTES="&lt;p&gt;Short title (no longer in use): Plasma volume expansion for pre-eclampsia&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2009-10-28 10:01:20 +0000" NOTES_MODIFIED_BY="Jill V Hampson" REVIEW_NO="0285" REVMAN_SUB_VERSION="5.0.22" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="9.0">
<COVER_SHEET MODIFIED="2009-11-11 14:00:52 +0100" MODIFIED_BY="Sonja Henderson">
<TITLE>Plasma volume expansion for treatment of pre-eclampsia</TITLE>
<CONTACT MODIFIED="2009-11-11 14:00:52 +0100" MODIFIED_BY="Sonja Henderson"><PERSON ID="7397" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Lelia</FIRST_NAME><LAST_NAME>Duley</LAST_NAME><POSITION>Professor of Obstetric Epidemiology</POSITION><EMAIL_1>l.duley@leeds.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Centre for Epidemiology and Biostatistics</DEPARTMENT><ORGANISATION>University of Leeds</ORGANISATION><ADDRESS_1>Bradford Royal Infirmary, Bradford Institute of Health Research</ADDRESS_1><ADDRESS_2>Temple Bank House, Duckworth Lane</ADDRESS_2><CITY>Bradford</CITY><ZIP>BD9 6RJ</ZIP><REGION>West Yorkshire</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1274 383410</PHONE_1><FAX_1>+44 1274 382767</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2009-11-11 14:00:52 +0100" MODIFIED_BY="Sonja Henderson"><PERSON ID="7397" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Lelia</FIRST_NAME><LAST_NAME>Duley</LAST_NAME><POSITION>Professor of Obstetric Epidemiology</POSITION><EMAIL_1>l.duley@leeds.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Centre for Epidemiology and Biostatistics</DEPARTMENT><ORGANISATION>University of Leeds</ORGANISATION><ADDRESS_1>Bradford Royal Infirmary, Bradford Institute of Health Research</ADDRESS_1><ADDRESS_2>Temple Bank House, Duckworth Lane</ADDRESS_2><CITY>Bradford</CITY><ZIP>BD9 6RJ</ZIP><REGION>West Yorkshire</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1274 383410</PHONE_1><FAX_1>+44 1274 382767</FAX_1></ADDRESS></PERSON><PERSON ID="16060" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>John</FIRST_NAME><LAST_NAME>Williams</LAST_NAME><POSITION>Consultant Obstetrician and Gynaecologist</POSITION><ADDRESS><DEPARTMENT>Countess of Chester Hospital NHS Trust</DEPARTMENT><ORGANISATION>Women and Children's Directorate</ORGANISATION><ADDRESS_1>Countess of Chester Hospital NHS Trust</ADDRESS_1><ADDRESS_2>Liverpool Road</ADDRESS_2><CITY>Chester</CITY><ZIP>CH2 1UL</ZIP><REGION>South Wirral</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1244 366403</PHONE_1><FAX_1>+44 1244 365003</FAX_1></ADDRESS></PERSON><PERSON ID="4691" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>David</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Henderson-Smart</LAST_NAME><POSITION>Director</POSITION><EMAIL_1>dhs@mail.usyd.edu.au</EMAIL_1><ADDRESS><DEPARTMENT>NSW Centre for Perinatal Health Services Research</DEPARTMENT><ORGANISATION>Queen Elizabeth II Research Institute</ORGANISATION><ADDRESS_1>Building DO2</ADDRESS_1><ADDRESS_2>University of Sydney</ADDRESS_2><CITY>Sydney</CITY><ZIP>2006</ZIP><REGION>NSW</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 2 93517318</PHONE_1><PHONE_2>+61 2 93517728</PHONE_2><FAX_1>+61 2 93517742</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2009-10-28 10:01:20 +0000" MODIFIED_BY="Jill V Hampson" NOTES="&lt;p&gt;Minor update: 7/25/01&lt;/p&gt;&lt;p&gt;New studies found and included or excluded: 12/22/00&lt;/p&gt;&lt;p&gt;Reformatted: 7/23/99&lt;/p&gt;" NOTES_MODIFIED="2009-10-28 10:01:20 +0000" NOTES_MODIFIED_BY="Jill V Hampson">
<UP_TO_DATE>
<DATE DAY="22" MONTH="12" YEAR="2000"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="1" MONTH="10" YEAR="2009"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR=""/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="1999"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="1999"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="1999"/>
</DATES>
<WHATS_NEW MODIFIED="2009-10-26 13:53:33 +0000" MODIFIED_BY="Jill V Hampson" NOTES="&lt;p&gt;Two new excluded studies added, UK 1986 and Germany 1993.&lt;/p&gt;" NOTES_MODIFIED="2009-10-26 13:53:33 +0000" NOTES_MODIFIED_BY="Jill V Hampson">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-10-26 13:53:33 +0000" MODIFIED_BY="Jill V Hampson">
<DATE DAY="1" MONTH="10" YEAR="2009"/>
<DESCRIPTION>
<P>Search updated. Fourteen reports added to <LINK TAG="AWAITING_STUDIES" TYPE="SECTION">Studies awaiting classification</LINK>.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2009-10-26 13:53:00 +0000" MODIFIED_BY="Jill V Hampson">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-10-26 13:53:00 +0000" MODIFIED_BY="Jill V Hampson">
<DATE DAY="20" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-09-21 14:20:11 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="25" MONTH="7" YEAR="2001"/>
<DESCRIPTION>
<P>Two new excluded studies added, <LINK REF="STD-UK-1986" TYPE="STUDY">UK 1986</LINK> and <LINK REF="STD-Germany-1993" TYPE="STUDY">Germany 1993</LINK>.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>NSW Centre for Perinatal Health Services Research, University of Sydney</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Countess of Chester Hospital NHS Trust</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Resource Centre for Randomised Trials, Oxford</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Medical Research Council</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2009-10-26 14:03:48 +0000" MODIFIED_BY="Jill V Hampson">
<SUMMARY MODIFIED="2008-09-21 14:11:02 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-09-21 14:10:57 +0100" MODIFIED_BY="[Empty name]">Plasma volume expansion for treatment of pre-eclampsia</TITLE>
<SUMMARY_BODY MODIFIED="2008-09-21 14:11:02 +0100" MODIFIED_BY="[Empty name]">
<P>Not enough evidence to show the effects of plasma volume expansion for women with pre-eclampsia.</P>
<P>Blood plasma volume increases gradually in women during the second half of pregnancy. The increase is usually greater for women with multiple pregnancies and less for those with small babies. Plasma volume is reduced in women with pre-eclampsia (pregnancy induced complication that includes high blood pressure). It is possible that women with pre-eclampsia might benefit from expanded plasma volume if it were to increase blood circulation for the mother and baby. The review of trials found there was not enough evidence to show the effects of plasma volume expansion for women with pre-eclampsia. More research is needed.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2009-10-26 14:00:25 +0000" MODIFIED_BY="Jill V Hampson">
<ABS_BACKGROUND>
<P>Plasma volume is reduced amongst women with pre-eclampsia. This association has led to the suggestion that expanding the plasma volume might improve maternal and uteroplacental circulation, and so potentially improve outcome for both the woman and her baby. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>The aim of this review was to assess the effects of plasma volume expansion for the treatment of women with pre-eclampsia.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2009-10-26 14:00:25 +0000" MODIFIED_BY="Jill V Hampson">
<P>We searched the Cochrane Pregnancy and Childbirth Group's Trials Register and the Cochrane Controlled Trials Register Issue 4, 2000 were searched for trials meeting the selection criteria.</P>
<P>We updated the search of the Cochrane Pregnancy and Childbirth Group's Trials Register on 1 October 2009 and added the results to the awaiting classification section.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised trials were included. Quasi-random designs were excluded. Participants were women with hypertension during pregnancy, with or without proteinuria. Women who were postpartum at trial entry were excluded. Interventions were any comparison of plasma volume expansion with no expansion, or of one plasma volume expander with another.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Data were extracted independently by two reviewers. Discrepancies were resolved by discussion. There was no blinding of authorship or results.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Three trials involving 61 women were included in this review. All compared a colloid solution with no plasma volume expansion. For every outcome reported, the confidence intervals are very wide and cross the no effect line.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2009-10-26 13:55:32 +0000" MODIFIED_BY="Jill V Hampson">
<P>There is insufficient evidence for any reliable estimates of the effects of plasma volume expansion for women with pre-eclampsia.</P>
<P>[Note: The 14 citations in the awaiting classification section of the review may alter the conclusions of the review once assessed.]</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2009-10-26 14:03:48 +0000" MODIFIED_BY="Jill V Hampson">
<BACKGROUND>
<P>During normal pregnancy there are considerable changes in blood pressure. Within the first weeks the woman's blood pressure falls, largely due to a general relaxation of muscles within the blood vessels (<LINK REF="REF-Hytten-1980" TYPE="REFERENCE">Hytten 1980</LINK>). From around the middle of pregnancy it rises slowly again until, at term, blood pressure is close to the level it was before pregnancy. Blood pressure during pregnancy can be influenced by many other factors, however, including time of day, physical activity, position and anxiety. High blood pressure alone has little effect on the outcome of pregnancy, but rises in blood pressure may be associated with other complications. Of these, the most common is pre-eclampsia. This is a multisystem disorder of pregnancy which commonly presents with raised blood pressure and proteinuria (<LINK REF="REF-Roberts-1993" TYPE="REFERENCE">Roberts 1993</LINK>), and occurs in between 2-8% of pregnancies (<LINK REF="REF-WHO-1988" TYPE="REFERENCE">WHO 1988</LINK>). Although the outcome for most of these pregnancies is good, women with pre-eclampsia have an increased risk of developing serious problems, such as kidney failure, liver failure, abnormalities of the clotting system, stroke, premature birth (birth before 37 completed weeks), stillbirth or death of the baby in the first few weeks of life (<LINK REF="REF-Redman-1993" TYPE="REFERENCE">Redman 1993</LINK>).</P>
<P>Plasma is the fluid portion of blood. It is composed of a mixture of many proteins in a crystalloid solution. The volume of maternal plasma increases progressively during the second half of pregnancy. The increase tends to be greatest for women with multiple pregnancies and least for those whose babies are small for gestational age (<LINK REF="REF-Redman-1984" TYPE="REFERENCE">Redman 1984</LINK>). Plasma volume is reduced amongst women with pre-eclampsia, and this reduction is associated with a low concentration of serum albumin (a type of protein). This association has led to the suggestion that, for women with pre-eclampsia, expanding the plasma volume might improve maternal and uteroplacental circulation (<LINK REF="REF-Redman-1984" TYPE="REFERENCE">Redman 1984</LINK>). This would only be worthwhile if it was reflected in clinically important improvement in outcome for both the woman and her baby. Women with hypertension alone do not have the same changes in plasma volume, and are therefore less likely to benefit from plasma expansion. </P>
<P>Early uncontrolled reports of plasma volume expansion suggested that such therapy might improve blood pressure control, reducing the need for additional antihypertensive drugs (<LINK REF="REF-Collins-1989" TYPE="REFERENCE">Collins 1989</LINK>). These reports advocated the intravenous infusion of colloid solutions, such as dextran and salt-poor albumin. These colloid solutions are of particles in a dispersion medium. More recently the use of crystalloid solutions have also been reported (<LINK REF="REF-Gallery-1993" TYPE="REFERENCE">Gallery 1993</LINK>). </P>
<P>Although there is little information about current clinical practice, anecdotally the use of plasma volume expanders for pre-eclampsia seems to be increasing. Most clinicians reserve such therapy for women with severe pre-eclampsia. There is no consensus on the type of agent to use, nor the amount and duration of treatment. Careful clinical monitoring is essential during and after plasma volume expansion, and some of those who use large volumes of expanders (&gt; 500 millilitre (ml)) advocate the use of invasive cardiovascular monitoring, such as Swan Ganz catheters, as well as central venous catheters. The invasive forms of monitoring involve placing catheters in the cardiac blood vessels or chambers, and have hazards of their own which should be considered when evaluating plasma expansion. </P>
<P>Two recent systematic reviews of plasma volume expansion for critically ill people who are not pregnant have raised concern about its effectiveness and safety. The first compared human albumin plasma expansion with no albumin and concluded that albumin increased the risk of death (<LINK REF="REF-Albumin-1999" TYPE="REFERENCE">Albumin 1999</LINK>). The second compared colloid solutions with crystalloids for fluid resuscitation, and demonstrated an increased mortality associated with the use of colloids (<LINK REF="REF-Schierhout-1999" TYPE="REFERENCE">Schierhout 1999</LINK>). In the UK, these reviews have recently led to a recommendation by the Committee of the Safety of Medicine that the indication for the use of human albumin solutions should focus on the use of albumin to replace lost fluids, and that 'hypoalbuminaemia' in itself was not an appropriate indication. Although none of the trials included in these reviews involved pregnant women, there is an urgent need to review the effects of both colloid and crystalloid solutions for women with pre-eclampsia.</P>
<P>Antihypertensive and anticonvulsant drug therapies for women with severe pre-eclampsia are evaluated in other reviews (<LINK REF="REF-Duley-2001" TYPE="REFERENCE">Duley 2001</LINK>; <LINK REF="REF-Duley-2001a" TYPE="REFERENCE">Duley 2001a</LINK>)</P>
</BACKGROUND>
<OBJECTIVES>
<P>To estimate the main effects for women and their babies of plasma volume expansion when used for the treatment of pre-eclampsia during pregnancy and labour.</P>
</OBJECTIVES>
<METHODS MODIFIED="2009-10-26 14:02:16 +0000" MODIFIED_BY="Jill V Hampson">
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>All randomised controlled trials of plasma volume expansion for treatment of hypertension during pregnancy. Quasi-randomised trials were excluded.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Women with hypertension during pregnancy, whether or not proteinuria was specified to be present. Although the primary aim was to evaluate plasma volume expansion for women with pre-eclampsia (hypertension plus proteinuria), women with hypertension alone were not excluded. </P>
<P>Women who were postpartum at trial entry were excluded.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Plasma volume expansion with either colloid or crystalloid solutions compared with no expansion. Also, comparisons of different types of plasma volume expansion.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>For the women: death, eclampsia; measures of serious maternal morbidity related to pre-eclampsia and plasma volume expansion (such as pulmonary oedema, renal failure, cardiac arrest, liver failure, stroke, and coagulopathy); need for antihypertensive drugs; caesarean section; use of health service resources (invasive monitoring, dialysis, ventilation, admission to intensive care, length of stay); women's views. </P>
<P>For the baby: perinatal and neonatal mortality; measures of serious neonatal morbidity (low Apgar scores, intraventricular haemorrhage); measures of infant and child development (such as cerebral palsy); use of health service resources (such as admission to special care nursery, ventilation, length of stay in hospital).</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2009-10-26 14:02:16 +0000" MODIFIED_BY="Jill V Hampson">
<ELECTRONIC_SEARCHES MODIFIED="2009-10-26 14:02:16 +0000" MODIFIED_BY="Jill V Hampson">
<P>We searched the Cochrane Pregnancy and Childbirth Group's Trials Register by contacting the Trials Search Co-ordinator (22 December 2000). We updated this search on 1 October 2009 and added the results to <LINK TAG="AWAITING_STUDIES" TYPE="SECTION">Studies awaiting classification</LINK>.</P>
<P>The Cochrane Pregnancy and Childbirth Group&#8217;s Trials Register is maintained by the Trials Search Co-ordinator and contains trials identified from:</P>
<OL>
<LI>quarterly searches of the Cochrane Central Register of Controlled Trials (CENTRAL);</LI>
<LI>weekly searches of MEDLINE;</LI>
<LI>handsearches of 30 journals and the proceedings of major conferences;</LI>
<LI>weekly current awareness alerts for a further 44 journals plus monthly BioMed Central email alerts.</LI>
</OL>
<P>Details of the search strategies for CENTRAL and MEDLINE, the list of handsearched journals and conference proceedings, and the list of journals reviewed via the current awareness service can be found in the &#8216;Specialized Register&#8217; section within the editorial information about the <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/PREG/frame.html">Cochrane Pregnancy and Childbirth Group</A>.</P>
<P>Trials identified through the searching activities described above are each assigned to a review topic (or topics). The Trials Search Co-ordinator searches the register for each review using the topic list rather than keywords.</P>
<P>In addition, The Cochrane Controlled Trials Register (<LINK REF="REF-CCTR-2000" TYPE="REFERENCE">CCTR 2000</LINK>) was searched using the search strategy in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> (last search Issue 4, 2000).</P>
<P>We did not apply any language restrictions.<BR/>
</P>
</ELECTRONIC_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>Data were extracted by Lelia Duley and John Williams. There was no blinding of authorship or results. Discrepancies were resolved by discussion. A quality score for concealment of allocation was assigned to each trial, using the following criteria:</P>
<P>(A) adequate concealment of allocation; <BR/>(B) unclear whether adequate concealment of allocation;<BR/>(C) inadequate concealment of allocation.</P>
<P>Quasi-randomised studies were excluded.</P>
<P>In addition, outcomes were excluded from the review if data for more than 20% of participants were not reported.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2009-10-26 14:03:48 +0000" MODIFIED_BY="Jill V Hampson">
<STUDY_DESCRIPTION>
<P>These studies all used colloid solutions for plasma volume expansion. None used crystalloid solutions. The women in one study (<LINK REF="STD-South-Africa-1989" TYPE="STUDY">South Africa 1989</LINK>) all had severe proteinuric pre-eclampsia. In the other two studies proteinuria was not present for all women at trial entry, and women with severe hypertension were excluded (<LINK REF="STD-UK-1993" TYPE="STUDY">UK 1993</LINK>; <LINK REF="STD-USA-1980" TYPE="STUDY">USA 1980</LINK>). </P>
<P>All women in one study (<LINK REF="STD-South-Africa-1989" TYPE="STUDY">South Africa 1989</LINK>) had a Swan Ganz catheter. In this trial (<LINK REF="STD-South-Africa-1989" TYPE="STUDY">South Africa 1989</LINK>) all women received magnesium sulphate, in another use of magnesium sulphate was reported as an outcome (<LINK REF="STD-USA-1980" TYPE="STUDY">USA 1980</LINK>).</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>The trials included in this review were all very small, and none describe, in adequate detail, the method used to conceal the allocation to treatment group.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2009-10-26 14:03:48 +0000" MODIFIED_BY="Jill V Hampson">
<P>Three trials involving 61 women were included in this review. Most women had pre-eclampsia, but two studies also recruited some women with hypertension but no proteinuria. All studies compared a colloid solution with no plasma volume expansion.</P>
<P>Two trials reported data on 'use of additional therapy' and caesarean section. Other outcomes were reported in single studies only. For every outcome reported, the confidence intervals are wide and cross the no effect line. (Fourteen reports from an updated search in October 2009 have been added to <LINK TAG="AWAITING_STUDIES" TYPE="SECTION">Studies awaiting classification</LINK>.)</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>This review includes a very small number of women. Two out of the three trials included some women with hypertension alone. These women are less likely to benefit from plasma volume expansion than women with pre-eclampsia. Future versions of this review may consider outcome for subgroups of women with different severity of disease, if there is any overall evidence of benefit.</P>
<P>Only two outcomes were reported by more than one of the three trials in the review. The confidence intervals for these two outcomes, 'use of additional therapy' and 'caesarean section' include everything from a halving in risk to a three times increase (relative risk (RR) 1.51, 95% confidence interval (CI) 0.73-3.11 and RR 1.46, 95% CI 0.75-2.85). This is insufficient evidence for any reliable estimates of the effects of plasma volume expansion for women with pre-eclampsia. </P>
<P>The trials in this review only evaluated colloid solutions. Data were not reported for many important outcomes, such as pulmonary oedema, renal failure, dialysis, admission to intensive care and perinatal morbidity. Even taken together, the studies included in this review are too small for any reliable conclusions about the overall effects of plasma volume expansion for women with pre-eclampsia. These data should also be considered alongside the evidence for critically ill non-pregnant people, for whom albumin, and possibly other colloids, increase mortality. Until further evidence becomes available, this suggests that colloid solutions should be used with considerable caution. </P>
<P>For crystalloid solutions, there are no reliable data from randomised trials on either their effectiveness or safety during pregnancy.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2009-10-26 14:03:19 +0000" MODIFIED_BY="Jill V Hampson">
<IMPLICATIONS_PRACTICE>
<P>The results of this review are inconclusive about the effects of plasma volume expansion for treatment of women with pre-eclampsia. There is a strong argument that the use of plasma volume expansion, especially colloid solutions, during pregnancy should be restricted to randomised trials.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2009-10-26 14:03:19 +0000" MODIFIED_BY="Jill V Hampson">
<P>The effectiveness and safety of colloid and crystalloid solutions when used for plasma volume expansion as treatment of pre-eclampsia can only be assessed in large randomised trials. Such trials should evaluate crystalloid solutions as, in non-pregnant people, these appear to be safer than colloid solutions. They have the added bonus of being considerably cheaper. Any such trials should probably be restricted to women with severe pre-eclampsia, as they have the most potential for benefit.</P>
<P>[Note: The 14 citations in the awaiting classification section of the review may alter the conclusions of the review once assessed.]</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>None.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.<BR/> </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Methods were developed and agreed by all three reviewers. Lelia Duley and John Williams checked for potentially eligible studies and extracted the data. Lelia Duley entered the data and drafted the text of the review, with comments and input from David Henderson-Smart and John Williams.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2009-10-26 13:52:36 +0000" MODIFIED_BY="Jill V Hampson">
<STUDIES MODIFIED="2009-10-26 13:52:36 +0000" MODIFIED_BY="Jill V Hampson">
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-South-Africa-1989" NAME="South Africa 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;[5283]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Belfort M, Uys P, Dommisse J, Davey DA</AU>
<TI>Haemodynamic changes in gestational proteinuric hypertension: the effects of rapid volume expansion and vasodilator therapy</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1989</YR>
<VL>96</VL>
<PG>634-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-UK-1993" NAME="UK 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;[10579]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lowe SA, Hetmanski DJ, Macdonald I, Boughton Pipkin F, Rubin PC</AU>
<TI>Intravenous volume expansion therapy in pregnancy-induced hypertension: the role of vasoactive hormones</TI>
<SO>Hypertension in Pregnancy</SO>
<YR>1993</YR>
<VL>12</VL>
<PG>139-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-USA-1980" NAME="USA 1980" YEAR="1980">
<REFERENCE NOTES="&lt;p&gt;[1810]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sehgal NN, Hitt JR</AU>
<TI>Plasma volume expansion in the treatment of pre-eclampsia</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1980</YR>
<VL>138</VL>
<PG>165-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2009-10-24 20:03:12 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Denmark-1984" NAME="Denmark 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rasmussen K, Bostofte E, Pedersen T</AU>
<TI>Volume expansion as treatment of severe pre-eclampsia</TI>
<SO>Scandinavian Journal of Clinical and Laboratory Investigation</SO>
<YR>1984</YR>
<VL>169</VL>
<PG>79-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Germany-1993" NAME="Germany 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tempelhoff GF, Heilmann L</AU>
<TI>The effect of plasma volume expansion on the utero-placental perfusion</TI>
<SO>Clinical Hemorheology</SO>
<YR>1993</YR>
<VL>13</VL>
<PG>729-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Netherlands-1992" NAME="Netherlands 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karsdorp VHM, van Vugt JMG, Dekker GA, van Geijn HP</AU>
<TI>Improvement of umbilical artery flow after maternal volume expansion</TI>
<SO>Journal of Perinatal Medicine</SO>
<YR>1992</YR>
<VL>Suppl 1</VL>
<PG>21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-South-Africa-1988" NAME="South Africa 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;[4550]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Allen DG, Davey DA, Dacre D</AU>
<TI>Plasma volume expansion in pregnancy hypertension</TI>
<SO>South African Medical Journal</SO>
<YR>1988</YR>
<VL>73</VL>
<PG>518-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-UK-1986" MODIFIED="2009-10-24 20:03:12 +0100" MODIFIED_BY="[Empty name]" NAME="UK 1986" YEAR="1986">
<REFERENCE MODIFIED="2009-10-24 20:03:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Buchan PC</AU>
<TI>Hypervolaemic haemodilution therapy in fulminating pre-eclampsia</TI>
<SO>Proceedings of the 24th British Congress of Obstetrics and Gynaecology; 1986 April 15-18; Cardiff, UK</SO>
<YR>1986</YR>
<PG>32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-USA-1989" MODIFIED="2009-10-24 20:01:50 +0100" MODIFIED_BY="[Empty name]" NAME="USA 1989" YEAR="">
<REFERENCE MODIFIED="2009-10-24 20:01:50 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;[3654]&lt;/p&gt;" NOTES_MODIFIED="2009-10-24 20:01:50 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Welt SI</AU>
<TI>Acute expansion of blood volume in the pre-eclamptic patient with prior hypertension, just prior to delivery</TI>
<SO>Personal communication</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2009-10-26 13:52:36 +0000" MODIFIED_BY="Jill V Hampson">
<STUDY DATA_SOURCE="PUB" ID="STD-Ganzevoort-2002" MODIFIED="2009-10-26 13:51:52 +0000" MODIFIED_BY="Jill V Hampson" NAME="Ganzevoort 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-10-26 13:51:52 +0000" MODIFIED_BY="Jill V Hampson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ganzevoort JW, Rep A, De Vries JIP, Wolf H</AU>
<TI>An ongoing randomized trial on plasma volume expansion in severe and early preeclampsia [abstract]</TI>
<SO>Hypertension in Pregnancy</SO>
<YR>2002</YR>
<VL>21</VL>
<NO>Suppl 1</NO>
<PG>46</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ganzevoort-2004" MODIFIED="2009-10-26 13:51:56 +0000" MODIFIED_BY="Jill V Hampson" NAME="Ganzevoort 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-10-26 13:51:56 +0000" MODIFIED_BY="Jill V Hampson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ganzevoort W, Rep A, Bonsel G, de Vries H, Wolf H</AU>
<TI>PVE has no beneficial effect in severe hypertensive complications of pregnancy [abstract]</TI>
<SO>Hypertension in Pregnancy</SO>
<YR>2004</YR>
<VL>23</VL>
<NO>Suppl 1</NO>
<PG>15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ganzevoort-2004a" MODIFIED="2009-10-26 13:52:00 +0000" MODIFIED_BY="Jill V Hampson" NAME="Ganzevoort 2004a" YEAR="2004">
<REFERENCE MODIFIED="2009-10-26 13:52:00 +0000" MODIFIED_BY="Jill V Hampson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ganzevoort W, Rep A, De Vries H, Bonsel G, Wolf H</AU>
<TI>Dynamic aspects of preeclampsia [abstract]</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2004</YR>
<VL>191</VL>
<NO>6 Suppl 1</NO>
<PG>S36</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ganzevoort-2004b" MODIFIED="2009-10-26 13:52:03 +0000" MODIFIED_BY="Jill V Hampson" NAME="Ganzevoort 2004b" YEAR="2004">
<REFERENCE MODIFIED="2009-10-26 13:52:03 +0000" MODIFIED_BY="Jill V Hampson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ganzevoort W, Rep A, Van Wassenaer AG, Kaspers AG, De Vries H, Bonsel G, et al</AU>
<TI>Long-term infant outcome of a trial of plasma volume expansion in women with preeclampsia remote from term [abstract]</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2004</YR>
<VL>191</VL>
<NO>6 Suppl 1</NO>
<PG>S36</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ganzevoort-2005" MODIFIED="2009-10-26 13:52:08 +0000" MODIFIED_BY="Jill V Hampson" NAME="Ganzevoort 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-10-26 13:52:08 +0000" MODIFIED_BY="Jill V Hampson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ganzevoort W, Rep A, Bonsel GJ, De Vries JIP, Wolf H, PETRA investigators</AU>
<TI>A randomized trial of plasma volume expansion in hypertensive disorders of pregnancy: influence on the pulsatility indices of the fetal umbilical artery and middle cerebral artery</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2005</YR>
<VL>192</VL>
<NO>1</NO>
<PG>233-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ganzevoort-2005a" MODIFIED="2009-10-26 13:52:11 +0000" MODIFIED_BY="Jill V Hampson" NAME="Ganzevoort 2005a" YEAR="2005">
<REFERENCE MODIFIED="2009-10-26 13:52:11 +0000" MODIFIED_BY="Jill V Hampson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ganzevoort W, Rep A, Bonsel GJ, Fetter WPF, van Sonderen L, de Vries JIP, et al</AU>
<TI>A randomised controlled trial comparing two temporising management strategies, one with and one without plasma volume expansion, for severe and early onset pre-eclampsia</TI>
<SO>BJOG: an international journal of obstetrics and gynaecology</SO>
<YR>2005</YR>
<VL>112</VL>
<PG>1358-68</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ganzevoort-2007" MODIFIED="2009-10-26 13:52:14 +0000" MODIFIED_BY="Jill V Hampson" NAME="Ganzevoort 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-10-26 13:52:14 +0000" MODIFIED_BY="Jill V Hampson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ganzevoort W, Rep A, Bonsel GJ, De Vries JI, Wolf H, for the PETRA investigators</AU>
<TI>Dynamics and incidence patterns of maternal complications in early-onset hypertension of pregnancy</TI>
<SO>BJOG: an international journal of obstetrics and gynaecology</SO>
<YR>2007</YR>
<VL>114</VL>
<NO>6</NO>
<PG>741-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heilmann-2001" MODIFIED="2009-10-26 13:52:17 +0000" MODIFIED_BY="Jill V Hampson" NAME="Heilmann 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-10-26 13:52:17 +0000" MODIFIED_BY="Jill V Hampson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heilmann L, Gerhold S, von Tempelhoff GF, Pollow K</AU>
<TI>The role of intravenous volume expansion in moderate pre-eclampsia</TI>
<SO>Clinical Hemorheology &amp; Microcirculation</SO>
<YR>2001</YR>
<VL>25</VL>
<NO>3-4</NO>
<PG>83-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Metsaars-2004" MODIFIED="2009-10-26 13:52:20 +0000" MODIFIED_BY="Jill V Hampson" NAME="Metsaars 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-10-26 13:52:20 +0000" MODIFIED_BY="Jill V Hampson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Metsaars W, Ganzevoort W, Karemakers J, Rang S, Wolf H</AU>
<TI>Effect of therapeutic plasma volume expansion on sympathetic hyperactivity in preeclampsia [abstract]</TI>
<SO>Hypertension in Pregnancy</SO>
<YR>2004</YR>
<NO>Suppl 1</NO>
<PG>73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Metsaars-2006" MODIFIED="2009-10-26 13:52:24 +0000" MODIFIED_BY="Jill V Hampson" NAME="Metsaars 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-10-26 13:52:24 +0000" MODIFIED_BY="Jill V Hampson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Metsaars WP, Ganzevoort W, Karemaker JM, Rang S, Wolf H</AU>
<TI>Increased sympathetic activity present in early hypertensive pregnancy is not lowered by plasma volume expansion</TI>
<SO>Hypertension in Pregnancy</SO>
<YR>2006</YR>
<VL>25</VL>
<NO>3</NO>
<PG>143-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rep-2003" MODIFIED="2009-10-26 13:52:27 +0000" MODIFIED_BY="Jill V Hampson" NAME="Rep 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-10-26 13:52:27 +0000" MODIFIED_BY="Jill V Hampson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rep A, Ganzevoort W, Wolf H</AU>
<TI>A randomized trial of temporizing management with or without plasma volume expansion in severe and early preeclampsia: maternal morbidity [abstract]</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2003</YR>
<VL>189</VL>
<NO>6 Suppl 1</NO>
<PG>S60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rep-2004" MODIFIED="2009-10-26 13:52:29 +0000" MODIFIED_BY="Jill V Hampson" NAME="Rep 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-10-26 13:52:29 +0000" MODIFIED_BY="Jill V Hampson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rep A, Ganzevoort W, Bonsel G, Wolf H, de Vries H</AU>
<TI>Temporising management with plasma volume expansion in severe and early preeclampsia [abstract]</TI>
<SO>Hypertension in Pregnancy</SO>
<YR>2004</YR>
<VL>23</VL>
<NO>Suppl 1</NO>
<PG>14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rep-2008" MODIFIED="2009-10-26 13:52:33 +0000" MODIFIED_BY="Jill V Hampson" NAME="Rep 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-10-26 13:52:33 +0000" MODIFIED_BY="Jill V Hampson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rep A, Ganzevoort W, Van Wassenaer AG, Bonsel GJ, Wolf H, De Vries JI, et al</AU>
<TI>One-year infant outcome in women with early-onset hypertensive disorders of pregnancy</TI>
<SO>BJOG: an international journal of obstetrics and gynaecology</SO>
<YR>2008</YR>
<VL>115</VL>
<NO>2</NO>
<PG>290-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spaanderman-2006" MODIFIED="2009-10-26 13:52:36 +0000" MODIFIED_BY="Jill V Hampson" NAME="Spaanderman 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-10-26 13:52:36 +0000" MODIFIED_BY="Jill V Hampson" PRIMARY="NO" TYPE="OTHER">
<AU>Spaanderman MEA</AU>
<TI>Cardiovascular and autonomic reactivity in women with a history of pre-eclampsia (ongoing trial)</TI>
<SO>ClinicalTrials.gov (http://clinicaltrials.gov/) (accessed 21 March 2006)</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2009-10-26 13:52:36 +0000" MODIFIED_BY="Jill V Hampson">
<ADDITIONAL_REFERENCES MODIFIED="2009-10-24 20:08:11 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Albumin-1999" MODIFIED="2009-10-24 20:07:46 +0100" MODIFIED_BY="[Empty name]" NAME="Albumin 1999" TYPE="COCHRANE_REVIEW">
<AU>The Albumin Reviewers (Alderson P, Bunn F, Lefebvre C, Li Wan Po A, Li L, Roberts I, Schierhout G)</AU>
<TI>Human albumin solution for resuscitation and volume expansion in critically ill patients</TI>
<SO>The Cochrane Library</SO>
<YR>1999</YR>
<NO>3</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CCTR-2000" MODIFIED="2009-10-24 20:08:11 +0100" MODIFIED_BY="[Empty name]" NAME="CCTR 2000" TYPE="OTHER">
<TI>The Cochrane Controlled Trials Register</TI>
<SO>The Cochrane Library</SO>
<YR>2000</YR>
<NO>4</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Collins-1989" NAME="Collins 1989" TYPE="BOOK_SECTION">
<AU>Collins R, Wallenburg HCS</AU>
<TI>Pharmacological prevention and treatment of hypertensive disorders in pregnancy</TI>
<SO>Effective Care in Pregnancy and Childbirth</SO>
<YR>1989</YR>
<PG>512-33</PG>
<ED>Chalmers I, Enkin MW, Keirse MJNC</ED>
<PB>Oxford University Press</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Duley-2001" NAME="Duley 2001" TYPE="COCHRANE_REVIEW">
<AU>Duley L, Henderson-Smart DJ</AU>
<TI>Drugs for rapid treatment of very high blood pressure during pregnancy (Cochrane Review)</TI>
<SO>The Cochrane Library</SO>
<YR>2001</YR>
<NO>2</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Duley-2001a" NAME="Duley 2001a" TYPE="COCHRANE_REVIEW">
<AU>Duley L, Gulmezoglu AM, Henderson-Smart D</AU>
<TI>Anticonvulsants for women with pre-eclampsia (Cochrane Review)</TI>
<SO>The Cochrane Library</SO>
<YR>2001</YR>
<NO>2</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gallery-1993" NAME="Gallery 1993" TYPE="JOURNAL_ARTICLE">
<AU>Gallery EDM</AU>
<TI>The role of volume expansion in clinical management of hypertensive women</TI>
<SO>Hypertension in Pregnancy</SO>
<YR>1993</YR>
<VL>12</VL>
<PG>9-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hytten-1980" NAME="Hytten 1980" TYPE="BOOK">
<AU>Hytten F, Chamberlain G</AU>
<SO>Clinical physiology in obstetrics</SO>
<YR>1980</YR>
<PB>Blackwell Scientific Publications</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Redman-1984" NAME="Redman 1984" TYPE="JOURNAL_ARTICLE">
<AU>Redman CWG</AU>
<TI>Maternal plasma volume and disorders of pregnancy</TI>
<SO>BMJ</SO>
<YR>1984</YR>
<VL>288</VL>
<PG>955-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Redman-1993" NAME="Redman 1993" TYPE="JOURNAL_ARTICLE">
<AU>Redman CWG, Roberts JM</AU>
<TI>Management of pre-eclampsia</TI>
<SO>Lancet</SO>
<YR>1993</YR>
<VL>341</VL>
<PG>1451-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Roberts-1993" NAME="Roberts 1993" TYPE="JOURNAL_ARTICLE">
<AU>Roberts JM, Redman CWG</AU>
<TI>Pre-eclampsia: more than pregnancy-induced hypertension</TI>
<SO>Lancet</SO>
<YR>1993</YR>
<VL>341</VL>
<PG>1447-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schierhout-1999" NAME="Schierhout 1999" TYPE="COCHRANE_REVIEW">
<AU>Schierhout G, Roberts I, Alderson P</AU>
<TI>Colloids versus crystalloids for fluid resuscitation in critically ill patients (Cochrane Review)</TI>
<SO>The Cochrane Library</SO>
<YR>1999</YR>
<NO>3</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1988" NAME="WHO 1988" TYPE="JOURNAL_ARTICLE">
<AU>World Health Organization International Collaborative Study of Hypertensive Disorders of Pregnancy</AU>
<TI>Geographic variation in the incidence of hypertension in pregnancy</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1988</YR>
<VL>158</VL>
<PG>80-3</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES>
<REFERENCE ID="REF-CDSR-2001" NAME="CDSR 2001" TYPE="COCHRANE_REVIEW">
<AU>Duley L, Williams J, Henderson-Smart DJ</AU>
<TI>Plasma volume expansion for treatment of women with pre-eclampsia (Cochrane Review)</TI>
<SO>The Cochrane Library</SO>
<YR>2001</YR>
<NO>3</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Duley-1995" NAME="Duley 1995" NOTES="&lt;p&gt;Duley L. Plasma volume expansion in pregnancy-induced hypertension. [ revised 02 June 1992] In: Enkin MW, Keirse MJNC, Renfrew MJ, Neilson JP, Crowther C (eds.) Pregnancy and Childbirth Module. In: The Cochrane Pregnancy and Childbirth Database [database on disk and CDROM]. The Cochrane Collaboration; Issue 2, Oxford: Update Software; 1995. Available from BMJ Publishing Group, London.&lt;/p&gt;" TYPE="OTHER">
<AU>Duley L</AU>
<TI>Plasma volume expansion in pregnancy-induced hypertension. [revised 02 June 1992] In: Enkin MW, Keirse MJNC, Renfrew MJ, Neilson JP, Crowther C (eds.) Pregnancy and Childbirth Module. In: The Cochrane Pregnancy and Childbirth Database [database on disk and CDROM]. The Cochrane Collaboration; Issue 2, Oxford: Update Software; 1995</TI>
<IDENTIFIERS/>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2009-10-26 13:52:36 +0000" MODIFIED_BY="Jill V Hampson"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2009-10-26 14:07:07 +0000" MODIFIED_BY="Jill V Hampson">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2009-10-26 14:07:07 +0000" MODIFIED_BY="Jill V Hampson" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2009-10-26 14:07:07 +0000" MODIFIED_BY="Jill V Hampson" STUDY_ID="STD-South-Africa-1989">
<CHAR_METHODS>
<P>'Randomly allocated', no further information.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>10 women with severe pre-eclampsia; BP &gt; 160/110 mmHg and at least 1g/litre proteinuria. No pre-existing hypertension, renal disease, heart disease or antihypertensives. Not in labour. All women had a Swan Ganz catheter inserted.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-10-26 14:07:07 +0000" MODIFIED_BY="Jill V Hampson">
<P>Expansion: 200 ml 3.5% haemaccel, then successive 200 ml over 30 minutes until pulmonary capillary wedge pressure increased by at least 16 mmHg. Then hydralazine 25 mg/200 ml infused to keep DBP 90-110 mmHg.<BR/>Control: hydralazine as above, but without prior infusion.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: caesarean section, mean gestation, change in pulmonary wedge pressure, cardiac index and systemic vascular resistance.<BR/>Baby: birthweight, Apgar at 1 and 5 minutes.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Four women had magnesium sulphate before entry, the others started it after hydralazine.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-UK-1993">
<CHAR_METHODS>
<P>'Predetermined randomisation schedule', no further information.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>15 women with PIH; SBP rise of 30 mmHg DBP rise of 15mmHg compared to BP before 20 weeks, twice at least six hours apart. Six women had proteinuria. Excluded if BP &gt; 170/110 mmHg, chronic hypertension, cardiac or renal disease, or antihypertensive agent started.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Expansion: haemaccel 500 ml over 25-30 minutes.<BR/>Control: hypotonic saline 500 ml over 25-30 minutes.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: antihypertensive therapy, mean blood pressure changes, median delay to delivery, changes in various haematological measures.<BR/>Baby: none.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-USA-1980">
<CHAR_METHODS>
<P>'Randomly assigned by blind draw' into three groups, no further information. Three women delivered and one withdrew before treatment.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>36 primiparous women with pre-eclampsia, defined as hypertension plus proteinuria and/or oedema. Age 15-33, gestation 28-40 weeks. Excluded if cardiac disease, renal or pulmonary insufficiency, severe pre-eclampsia (if required antihypertensive drugs and prompt delivery).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Expansion: (a) plasmanate 500 ml over eight hours day one, 250 ml over four hours day two (b) dextran 40 1000 ml over eight hours day one, 500 ml over four hours day two.<BR/>Control: 5% dextrose in distilled water 1000 ml over eight hours day one, 500ml over four hours day two.<BR/>Treatment started after 24 hours assessment, with bed rest, sedatives and magnesium sulphate as indicated.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: use of magnesium sulphate, caesarean section, preterm delivery, placental abruption, change in urine output and haematocrit.<BR/>Baby: death.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Twins mentioned in the text, but not clear how many and in which group.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>BP=blood pressure; DBP=diastolic blood pressure; mg=milligram; ml=millilitre; mmHg=millimeter of mercury; PIH=pregnancy induced hypertension; SBP=systolic blood pressure</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Denmark-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case series, no control group.</P>
<P>Participants: 14 women with pre-eclampsia.<BR/>Intervention: plasma volume expansion with albumin (100 ml/hr), plus sedation and antihypertensive drugs.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Germany-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>The women did not have pre-eclampsia and no clinical outcomes reported.</P>
<P>Study design: double blind randomised.<BR/>Participants: 12 women with haemoconcentration (Hb &gt; 13g/dl).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Netherlands-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised trial. Available as an abstract only.</P>
<P>Participants: 14 women with absent or reversed end diastolic flow in the umbilical artery.<BR/>Interventions: Plasma volume expansion versus bed rest and antihypertensive drugs.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-South-Africa-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Quasi-randomised trial, every third women used as a control. No outcomes reported.</P>
<P>Participants: 21 women with DBP 90-119 mmHg, and &gt; 20 weeks gestation.<BR/>Interventions: human serum 500 ml over 90 minutes versus no volume expansion.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-UK-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Published as an abstract only. 'Randomly allocated' no further information. No clinical outcomes reported.</P>
<P>Participants: 15 women with severe pre-eclampsia.<BR/>Intervention: 100mg salt poor albumin by intravenous infusion until delivery.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-USA-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Quasi randomised trial. Registered as an ongoing study in 1987, and said by author to have been completed in 1989.</P>
<P>Participants: 62 women with pre-eclampsia prior to delivery, &lt; 37 weeks gestation.<BR/>Intervention: 4 different ways for rapidly expanding plasma volume.<BR/>Outcomes: No clinical outcomes, laboratory results only.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>DBP=diastolic blood pressure; hr=hour; ml=millilitre; mmHg=millimeter of mercury</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2009-10-26 13:52:36 +0000" MODIFIED_BY="Jill V Hampson" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR STUDY_ID="STD-Ganzevoort-2002">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Ganzevoort-2004">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Ganzevoort-2004a">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Ganzevoort-2004b">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Ganzevoort-2005">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Ganzevoort-2005a">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Ganzevoort-2007">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Heilmann-2001">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Metsaars-2004">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Metsaars-2006">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Rep-2003">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Rep-2004">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Rep-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Spaanderman-2006">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-South-Africa-1989">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-UK-1993">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-USA-1980">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Plasma volume expansion versus no expansion</NAME>
<DICH_OUTCOME CHI2="0.9811334526658663" CI_END="3.1065588332728877" CI_START="0.7332388190014982" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5092546273136567" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.49227958287230095" LOG_CI_START="-0.1347545507585581" LOG_EFFECT_SIZE="0.17876251605687143" METHOD="MH" NO="1" P_CHI2="0.32191935672201444" P_Q="0.0" P_Z="0.26376321073646336" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="26" TOTAL_2="21" WEIGHT="100.0" Z="1.117540734914748">
<NAME>use of additional drug therapy</NAME>
<GROUP_LABEL_1>Expansion</GROUP_LABEL_1>
<GROUP_LABEL_2>No expansion</GROUP_LABEL_2>
<GRAPH_LABEL_1>Expansion better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Expansion worse</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.962965365923561" CI_START="0.01765987839175916" DF="0" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.901074826812404" LOG_CI_START="-1.7530122913569661" LOG_EFFECT_SIZE="-0.42596873227228116" NO="1" P_CHI2="1.0" P_Z="0.5292637285358863" STUDIES="1" TAU2="0.0" TOTAL_1="7" TOTAL_2="8" WEIGHT="19.209604802401202" Z="0.6291303462334786">
<NAME>antihypertensive drug</NAME>
<DICH_DATA CI_END="7.962965365923558" CI_START="0.01765987839175916" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9010748268124039" LOG_CI_START="-1.7530122913569661" LOG_EFFECT_SIZE="-0.42596873227228116" ORDER="14442" O_E="0.0" SE="1.5590239111558089" STUDY_ID="STD-UK-1993" TOTAL_1="7" TOTAL_2="8" VAR="2.4305555555555554" WEIGHT="19.209604802401202"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.775090876002445" CI_START="0.8382986909611387" DF="0" EFFECT_SIZE="1.7789473684210526" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="5" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.5769274106596072" LOG_CI_START="-0.07660121200995575" LOG_EFFECT_SIZE="0.2501630993248258" NO="2" P_CHI2="1.0" P_Z="0.13348428729539466" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="13" WEIGHT="80.7903951975988" Z="1.5005024965386577">
<NAME>magnesium sulphate</NAME>
<DICH_DATA CI_END="3.775090876002445" CI_START="0.8382986909611386" EFFECT_SIZE="1.7789473684210526" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="5" LOG_CI_END="0.5769274106596072" LOG_CI_START="-0.07660121200995579" LOG_EFFECT_SIZE="0.2501630993248258" ORDER="14443" O_E="0.0" SE="0.3838859479749573" STUDY_ID="STD-USA-1980" TOTAL_1="19" TOTAL_2="13" VAR="0.1473684210526316" WEIGHT="80.7903951975988"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.05694129264704181" CI_END="2.852362758522686" CI_START="0.7469800824625568" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4596774193548387" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.45520475750737144" LOG_CI_START="-0.1266909780934725" LOG_EFFECT_SIZE="0.16425688970694943" METHOD="MH" NO="2" P_CHI2="0.8113973515928468" P_Q="0.0" P_Z="0.2685045728609272" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="24" TOTAL_2="18" WEIGHT="100.0" Z="1.1065129656115045">
<NAME>caesarean section</NAME>
<GROUP_LABEL_1>Expansion</GROUP_LABEL_1>
<GROUP_LABEL_2>No expansion</GROUP_LABEL_2>
<GRAPH_LABEL_1>Expansion better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Expansion worse</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.0860393758160356" CI_START="0.5760709962774482" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.48940146307208326" LOG_CI_START="-0.23952398985548334" LOG_EFFECT_SIZE="0.12493873660829992" ORDER="14444" O_E="0.0" SE="0.42817441928883754" STUDY_ID="STD-South-Africa-1989" TOTAL_1="5" TOTAL_2="5" VAR="0.18333333333333324" WEIGHT="38.70967741935483"/>
<DICH_DATA CI_END="3.9534214920771737" CI_START="0.5994754743773897" EFFECT_SIZE="1.5394736842105263" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" LOG_CI_END="0.5969731189027868" LOG_CI_START="-0.2222285799720462" LOG_EFFECT_SIZE="0.18737226946537028" ORDER="14445" O_E="0.0" SE="0.48120313303288637" STUDY_ID="STD-USA-1980" TOTAL_1="19" TOTAL_2="13" VAR="0.23155645524066576" WEIGHT="61.29032258064516"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="13.573365083058116" CI_START="0.13795961177104224" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.368421052631579" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="1.1326875304769781" LOG_CI_START="-0.8602480364410001" LOG_EFFECT_SIZE="0.136219747017989" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.7887515134749941" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="19" TOTAL_2="13" WEIGHT="100.0" Z="0.2679321926612031">
<NAME>placental abruption</NAME>
<GROUP_LABEL_1>Expansion</GROUP_LABEL_1>
<GROUP_LABEL_2>No expansion</GROUP_LABEL_2>
<GRAPH_LABEL_1>Expansion better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Expansion worse</GRAPH_LABEL_2>
<DICH_DATA CI_END="13.573365083058116" CI_START="0.13795961177104224" EFFECT_SIZE="1.368421052631579" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.1326875304769781" LOG_CI_START="-0.8602480364410001" LOG_EFFECT_SIZE="0.136219747017989" ORDER="14446" O_E="0.0" SE="1.1706602171977805" STUDY_ID="STD-USA-1980" TOTAL_1="19" TOTAL_2="13" VAR="1.3704453441295548" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.511250450819526" CI_START="0.4150902721317859" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.368421052631579" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.6542969384676018" LOG_CI_START="-0.38185744443162384" LOG_EFFECT_SIZE="0.136219747017989" METHOD="MH" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="0.606315591124195" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="19" TOTAL_2="13" WEIGHT="100.0" Z="0.5153398036909764">
<NAME>preterm delivery</NAME>
<GROUP_LABEL_1>Expansion</GROUP_LABEL_1>
<GROUP_LABEL_2>No expansion</GROUP_LABEL_2>
<GRAPH_LABEL_1>Expansion better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Expansion worse</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.511250450819526" CI_START="0.4150902721317859" EFFECT_SIZE="1.368421052631579" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.6542969384676018" LOG_CI_START="-0.38185744443162384" LOG_EFFECT_SIZE="0.136219747017989" ORDER="14447" O_E="0.0" SE="0.6086422135619207" STUDY_ID="STD-USA-1980" TOTAL_1="19" TOTAL_2="13" VAR="0.37044534412955465" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="67.44526527238526" CI_START="0.18162876149314572" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.5000000000000004" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="1.8289514671546878" LOG_CI_START="-0.7408153784541364" LOG_EFFECT_SIZE="0.5440680443502757" METHOD="MH" NO="6" P_CHI2="1.0" P_Q="0.0" P_Z="0.40658256247856195" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="19" TOTAL_2="13" WEIGHT="100.0" Z="0.8299225853021253">
<NAME>perinatal death</NAME>
<GROUP_LABEL_1>Expansion</GROUP_LABEL_1>
<GROUP_LABEL_2>No expansion</GROUP_LABEL_2>
<GRAPH_LABEL_1>Expansion better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Expansion worse</GRAPH_LABEL_2>
<DICH_DATA CI_END="67.44526527238526" CI_START="0.18162876149314572" EFFECT_SIZE="3.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.8289514671546878" LOG_CI_START="-0.7408153784541364" LOG_EFFECT_SIZE="0.5440680443502757" ORDER="14448" O_E="0.0" SE="1.5094937656616634" STUDY_ID="STD-USA-1980" TOTAL_1="19" TOTAL_2="13" VAR="2.2785714285714285" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.2219367376379138" CI_START="0.766429621741243" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5714285714285714" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.508117008844064" LOG_CI_START="-0.11552771855612762" LOG_EFFECT_SIZE="0.1962946451439682" METHOD="MH" NO="7" P_CHI2="1.0" P_Q="0.0" P_Z="0.2172726787339797" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="5" TOTAL_2="5" WEIGHT="100.0" Z="1.2338128358563583">
<NAME>birthweight &lt; 2500 g</NAME>
<GROUP_LABEL_1>Expansion</GROUP_LABEL_1>
<GROUP_LABEL_2>No expansion</GROUP_LABEL_2>
<GRAPH_LABEL_1>Expansion better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Expansion worse</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.2219367376379133" CI_START="0.7664296217412432" EFFECT_SIZE="1.5714285714285714" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.508117008844064" LOG_CI_START="-0.11552771855612748" LOG_EFFECT_SIZE="0.1962946451439682" ORDER="14449" O_E="0.0" SE="0.3663319999660611" STUDY_ID="STD-South-Africa-1989" TOTAL_1="5" TOTAL_2="5" VAR="0.13419913419913418" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="19.92783283076195" CI_START="0.45162964163905406" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="1.2994600713639508" LOG_CI_START="-0.34521756192462616" LOG_EFFECT_SIZE="0.47712125471966244" METHOD="MH" NO="8" P_CHI2="1.0" P_Q="0.0" P_Z="0.25546651089494854" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="5" TOTAL_2="5" WEIGHT="100.0" Z="1.1371717552202145">
<NAME>Apgar at 5 minutes &lt; 7</NAME>
<GROUP_LABEL_1>Expansion</GROUP_LABEL_1>
<GROUP_LABEL_2>No expansion</GROUP_LABEL_2>
<GRAPH_LABEL_1>Expansion better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Expansion worse</GRAPH_LABEL_2>
<DICH_DATA CI_END="19.92783283076195" CI_START="0.45162964163905406" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.2994600713639508" LOG_CI_START="-0.34521756192462616" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="14450" O_E="0.0" SE="0.9660917830792959" STUDY_ID="STD-South-Africa-1989" TOTAL_1="5" TOTAL_2="5" VAR="0.9333333333333333" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-09-21 14:15:52 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2008-09-21 14:15:52 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-09-21 14:15:13 +0100" MODIFIED_BY="[Empty name]">Search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-09-21 14:15:52 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>PLASMA-VOLUME*:ME</LI>
<LI>(PLASMA next VOLUME)</LI>
<LI>EXPAN*</LI>
<LI>(#1 or #2)</LI>
<LI>(#3 and #4)</LI>
<LI>(PLASMA next EXPAN*)</LI>
<LI>PLASMA-SUBSTITUTES*:ME</LI>
<LI>ALBUMIN</LI>
<LI>(#5 or #6 or #7 or #8)</LI>
<LI>PREGNANCY-TOXEMIAS*:ME</LI>
<LI>PREECLAMP*</LI>
<LI>PRE-ECLAMP*</LI>
<LI>(PRE next ECLAMP*)</LI>
<LI>ECLAMP*</LI>
<LI>(HYPERTENS* and PREGNAN*)</LI>
<LI>(((((#10 or #11) or #12) or #13) or #14) or #15)</LI>
<LI>(#16 and #9)</LI>
</OL>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>